SCHEMBL491687

SCHEMBL491687

COc1cc(NS(=O)(=O)c2ccc(Cl)cc2)c(C(=O)Nc2ccc(S(=O)(=O)N3C[C@@H](C)O[C@@H](C)C3)cc2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.55
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 1/20 0.53
KMT2A Q03164 6/20 0.51
MEN1 O00255 4/20 0.51
AVPR2 P30518 1/20 0.49
GPR27 Q9NS67 1/20 0.49
SLC10A2 Q12908 1/20 0.48
SLC10A1 Q14973 1/20 0.48
SLC10A6 Q3KNW5 1/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MAPK1 P28482 4/20 0.48
DDIT3 P35638 1/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
HSD17B10 Q99714 1/20 0.47
RXFP1 Q9HBX9 2/20 0.47
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491688 1.00 THRB (0.55) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491849 0.99 THRB (0.54) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491847 0.99 THRB (0.54) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL492532 0.90 ALDH1A1 (0.56) ALDH1A1KDM4EKMT2AMEN1AVPR2
SCHEMBL491976 0.88 THRB (0.59) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491977 0.88 THRB (0.59) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491991 0.88 THRB (0.59) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491990 0.88 THRB (0.59) THRBALDH1A1KDM4EKMT2AMEN1
SCHEMBL491750 0.87 KMT2A (0.64) ALDH1A1KDM4EKMT2AMEN1AVPR2
SCHEMBL492332 0.87 ALDH1A1 (0.60) ALDH1A1KDM4EKMT2AMEN1AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518998-B2 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-27 US claimed
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH 2012-05-03 US claimed
US-8106213-B2 For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-01-31 US claimed
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-27 US claimed
EP-2207541-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN Sanofi-Aventis Deutschland GmbH (DE) 2010-07-21 EP claimed
WO-2009043495-A1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-09 WO claimed
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them TELEVOX SOFTWARE, INCORPORATED 2008-04-24 US claimed
EP-1095016-B1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2005-11-09 EP claimed
US-20040186145-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH. 2004-09-23 US claimed
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-05-23 US claimed
US-6335334-B1 HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-01 US claimed
EP-2207541-B1 USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN SANOFI AVENTIS DEUTSCHLAND (DE) 2014-10-29 EP disclosed
US-8541410-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-09-24 US disclosed
US-8518998-B2 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-27 US disclosed
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH 2012-05-03 US disclosed
EP-1095016-B1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2005-11-09 EP disclosed
US-20040186145-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH. 2004-09-23 US disclosed
US-6335334-B1 HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-01 US disclosed
EP-1095016-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-05-02 EP disclosed
WO-2000002851-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM GUCY1A1, GUCY1B1, GUCY1A2 THRB 2605/4885ALDH1A1 457/4885KDM4E 3935/4885
US-20110021505-A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain SCN1A, SCN2A, CACNA1A THRB 1294/4885ALDH1A1 494/4885KDM4E 1745/4885
US-20040186145-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1B1, GUCY1A2 THRB 2581/4885ALDH1A1 860/4885KDM4E 4029/4885
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1B1, GUCY1A2 THRB 2581/4885ALDH1A1 860/4885KDM4E 4029/4885
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1A2, GUCY1B1 THRB 2710/4885ALDH1A1 391/4885KDM4E 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.